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Abstract
Human Papillomavirus (HPV) is the most common cause of cervical cancer. Cervical cancer being the second most
common cancer after lung cancer, affecting women of different age groups; has a prevalence of about 20% in
young sexually active women. Among different types of HPV, HPV16 the major strain causing this cancer and is
sexually transmitted had been unnoticed for decades. Keeping in mind the multiple risk factors related with
cervical cancer such as early age sexual activities, teenage pregnancies, smoking, use of oral contraceptives, having
multiple sex partners, hormone replacement therapies and various other unknown factors lead to the onset of the
disease. Awareness for various diagnostic procedures such as Pap smears screening prove to be an effective way in
eradicating the oncogenic potential of HPV.
Background
Human papilloma viruses (HPV) are small non envel-
oped virus containing double stranded DNA as their
genetic material and are about 55 nm in size. Their gen-
ome has three functional coding regions; E: a gene cod-
ing early viral function, L: a gene coding late viral
function and LCR: a long control region which lies
between E and L. They appear to show similarity with
plyoma viruses and consist of about 72 capsomeres. The
papilloma viruses and its viral nature were first seen in
human warts in 1907, and the first papilloma virus was
isolated from a rabbit that was identified by Richard
Shoppe in the year 1983. Even it was an early start for
the detection of human papilloma viruses; this topic
remained closed till 1970’s. Studies related with papil-
loma viruses were allowed to move forth only when
cervical cancer’s proximity with HPV was proved and
with its increasing significance in the field of molecular
virology [1].
Human papilloma virus is known to be the main rea-
son for cervical carcinomas. Back in 1976 HPV was seen
with its involvement in the successful development of
cervical tumours and since then various epidemiological
and biological statistics has justified this observation [2].
HPV viruses are one of the most common viruses which
are transmitted sexually and are found in both men and
women. Its ratio is much higher in western countries as
compared to other regions of the world.
Prevalence and Incidence
Cervical cancer as the most prevalent cancer in women
in the coming years is the main cause of death, espe-
cially in young women. Its ratio varies all over the
world, but a significantly high ratio has been seen in the
western countries. By statistical and geographical analy-
s i si tp r o v e st ob eh i g h e ri nN a t i v eA m e r i c a nw o m e n
than in Caucasian women. It was also found common in
Hispanic and African American women [3]. According
to the World Health Organization (WHO) statistics,
there are approximately 500,000 new cases registered
each year out of which 250,000 cases are fatal. This
alarming situation in the coming years for papilloma-
viruses has lead molecular virologists world wide to go
deep into pathogenesis and bring out solutions to its
therapeutic potential [4]. According to the most recent
reports, in the United States of America (USA) women
are prone to this infection twice than men in all regions
of the world including USA and the prevalence of HPV
is much higher in women than men. The reported over-
all prevalence rate of HPV in women irrespective of
races was 17.9%, while men showed a comparably lower
rate of 8%. African Americans had the ratio of 20 to
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to be about 12.5%. People who had multiple sex part-
ners during their lifetime were on a higher risk of HPV
infection as the frequency of HPV was seen to be 20.1%
compared 7% in those patients who had only one sexual
partner throughout their sexual lives [5].
Different types of HPV
About 100 different subtypes of HPV with distinguished
variations in its genetic and oncogenic potential are
known. The subtypes which specifically affect the ano-
genital tract are HPV subtypes 16, 18, 31, 33, 35, 39, 45,
51, 52, 56, 58, 66 and 69 [3]. These specific subtypes
can be further classified or described under high-risk
and low-risk parameters. These specific subtypes possess
a remarkable ability to cause malignancy and play a
pivotal role in development of various tumours [2]. The
HPV type 6 and 11 are considered as the low risk geni-
tal types while on the other hand HPV 16 and 18 con-
tribute towards malignancy and fall under the high risk
genital types [6]. Prior to a confirmed malignancy of the
cervical region, there appears a cervical intraepithelial
neoplasia (CIN) which can indicate it towards a high
risk HPV infection and this infection is actually the pro-
longed interval with specific symptoms till the develop-
ment of a tumour [2]. It is now an established fact that
papillomaviruses are highly species specific.
Structure of HPV 16
HPV16 is one of the most prominent strains of HPV
which is typically classified under high risk type infec-
tion as mentioned earlier. It is associated with additional
infections namely lichen sclerosis and not only it leads
to cervical cancer but is also related with vaginal, vulval,
anal and penile cancers or benign growths specifically in
these areas, but the most prominent and hazardous
damage caused by HPV 16 strain is cervical cancer [7].
The HPV 16 is a small non enveloped virus containing
double stranded DNA as its genetic material. Its genome
has seven functional coding regions; E1/E2: Code pro-
teins that control the function of E6 and E7 genes, E4: a
gene coding a protein the function of this protein is lar-
gely unknown but may control virus release from cell,
E5: codes for a hydrophobic protein which enhances
immortalization of the cell, E6: gene coding proteins
which inhibit negative regulators of the cell cycle and
further inhibit p53 which is a transcription factor for
apoptosis, E7: codes for viral protein that bind to the
retinoblastoma tumor suppressor proteins thereby per-
mitting the cell to progress through the cell cycle in the
absence of normal mitogenic signals, L1/L2: Code for
structural proteins for late viral function and formation
of complete virus particles and LCR: a long control
region which lies between E and L that is necessary for
normal virus replication and control of gene expression
(Figure 1).
Pathogenesis of HPV 16 and its Replication
Replication of HPV 16 is initiated with the replication of
viral DNA in contrast with the cellular chromosomes. In
this process of division, one daughter cell moves apart
from the basal lamina to undergo differentiation. Infec-
tion in the basal lamina can persist for years because, of
the restriction of virion production to only differentiated
cells. The E1 and E2 proteins are supposed to be the
recognition factors and regulators for early viral tran-
scription. Icosahedral capsid for virion generation are
formed by L1 and L2 [1].
HPV 16 affects approximately 20% of the adult popu-
lation particularly in western countries [8]. It sometimes
causes warts which are flat in appearance called condy-
loma planum and they appear to be less visible. Others
include cauliflower like warts mostly seen in the genital
areas [9]. The three major onco-proteins which have
gained importance in HPV and its relation with cervical
cancer are E5,E 6,E 7 respectively. These proteins are
associated with cervical cancer studied both in vitro and
in vivo [10]. The proteins E6 and E7 are important for
the inhibition of tumour suppressor genes namely p53
and pRb [11]. As far as E5 is concerned it is known to
have weak oncogenic properties which result in
increased activity of epidermal growth factor receptor
(EGFR) and there by inhibiting the major histocompat-
ibility complex expression [11]. For a crucial step to
initiate in carcinogenesis it is very necessary that
the viral DNA integrates into the host genome. To
Figure 1 The figure shows the location of the major open
reading frames which possess the ability to encode proteins
and the long control regions which have the ability of
transcription and replication control elements (Adapted from
Molecular biologists for Oncologists.1996, 2
nd edd., Editors “J.
R.Yarnold, M.R.Stratton, T.J.McmMillan” publishers, Chapman
and Hall).
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nancy it is very important to jot down that E2 and E1
are the two proteins which play a leading role in control
of transcription and replication and in the absence or
loss of activity of these proteins deregulation of E6 and
E7 onco-proteins results [12].
HPV I6 E6 protein comprises of about 151 amino
acids, these proteins are confined to the nuclear matrix
and non-nuclear membrane fraction. Their major func-
tion is in zinc binding. This E6 protein is related with
high risk HPV associated with wild type p53 tumour
suppressor protein. To get associated with p53, the E6
protein needs a cellular protein of about 100-kDa and is
known as E6-AP [13]. The E6 protein favours abnormal
cell growth by the process of binding and rapidly target-
ing the p53 protein [14]. This p53 protein shows degra-
dation by the ubiquitin pathway and the cell is allowed
to go from the p53 associated negative growth control
[15]. The E6-E6 AP complex specifically target ubiquitin
targeted substrates. It also shows p53 disruption and
p53 mediated apoptosis [16]. HPV E7 proteins are small
proteins consisting of 98 amino acids and zinc binding
phosphoproteins are confined in the nucleus. This high
risk HPV E7 protein has a higher binding affinity for
pRb protein [17].
The mutational analysis reveals that an E7 protein
plays a major role in transformation and has proved its
ability with interference with pRb function. This inter-
ference of E7 protein with the pRb function contributes
in the development of malignancy. pRb is also a tumour
suppressor gene and is the main mutant allele of Rb
present in the germline of an individual which is linked
to a predisposition to retinal tumour [18]. The major
finding that how pRb functions in growth control lies
with the proof of its binding ability and inhibition of
various transcription factors namely E2 F-1and cMyc
proteins. These cMyc and E2 F-1 proteins activate some
of the essential genes which are required for DNA
synthesis. The HPV infected cell typically shows that
pRb is inactive throughout in association with binding
of the E7 proteins. This decreased or inappropriate
release of transcription factors favours the deregulated
expression of genes which are related with normal con-
trol and cell division [19].
More striking evidence reported by several studies is
that E7 possesses and has the capability of overcoming
DNA damage induced p53-dependant G1 arrest. In the
precancerous lesions the loss of control point favours
and allows the DNA damaged cells to enter the normal
cell division initiating to cancerous or tumourigenic
mutations. This evidence of mutations is well supported
by recent reports that deregulate expression of E2 Fi n
rat fibroblasts which leads to S phase entry in the cell
cycle and apoptosis in p53 [20]. Moreover expression of
high risk HPV oncogenes in this DNA damage response
is most probably interfered or disrupted at two points.
At first the E6 protein by targeting the p53 protein for
degradation inhibits the transcriptional activation of the
kinase inhibitor and secondly expression of the E7 pro-
teins can result in the constitutive inactivation of pRb
and hence the deregulation of E2 F1 takes place [20].
Many reviews and studies had focused on the
mechanisms and significant properties of E6 and E7 pro-
teins and it is very essential to bring into light the
detailed analysis of these studies on the specific regions
of HPV16 E7 proteins [6]. For mapping the contribution
of these particular events of the protein sequence point
mutations and deletions were used. In vitro studies have
revealed that the biological properties of HPV16 E7 are
also related with in vivo functions which include immor-
talization and transformation alone or in cooperation
with ras.
Causes of HPV16
As far as the causes of HPV16/HPV18 are concerned
sexual behaviour is the strongest factor for this increas-
ing malignancy. Despite sexual behaviour other factors
might also be involved in its infection. It is important to
note that all HPV infections does not lead to a malig-
nancy however, the two strains of HPV that are HPV16
and HPV18 mainly contributes in the development of
cervical cancer. Other factors include smoking, extensive
use of oral contraceptives and history of having sexually
transmitted diseases [21]. Mutations in ras, fos and
other related oncogenes has also been detected in cervi-
cal cancer cell lines but their in vivo role and prolifera-
tion is still unpredicted [21].
Other factors that enhance cervical cancer include
impaired immune response, persistence of virus, smok-
ing and administration of steroid hormones [21]. Loss of
tumour suppressor genes and the activation of onco-
genes may also play an important role. For cervical car-
cinogenesis, steroid hormones (estrogens and
progesterone) play a role in the initiation and successful
development of progression of the disease. Women who
take estradiol have been reported to develop HSIL
lesions that ultimately lead to the progressive one
[22,23]. Estrogen affects the immune response as well
[24,25].
Haptoglobulin which was an acute phase glycoprotein
present in body fluids is reported to be in relation with
tumour and infection which modulate the Th1/Th2
response [26-29]. The same factors are considered
responsible for the immune tolerance related to human
fertility [26,27,30]. Apart from these mechanisms the
genetic Hp polymorphism greatly enhances the female
susceptibility for HPV cervical infection and neoplasia
but also shows its relative response to the environmental
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can be in the form of both hormone replacement ther-
apy and oral contraceptive [26,27]. Keeping in view the
other related factors the most prominent evidence for
cervical cancer reported 80% of the studies are sexual
behaviour and the changes related in sexual behaviour.
The factor of sexual behaviour suffers lack of data, but
according to the reported data on the subject, the
increased ratio of CIN incidence among women ranging
between 25 to 39 years. It may be due to the drastic
changes in immigration, mixing patterns of population,
population migration and economic migration [28].
HPV 16 among men
HPV affects not only women, but this virus is even con-
tracted by men. Men do have the ability to transmit it
but unlike women in men there is no such confirmed
lab test available such as women do have Pap smear
tests [31].
HPV16 among women
HPV16 which ultimately leads to cervical cancer stays
and incubates in the body for a prolonged period of
time before the onset of malignant cervical cancer [32].
Sometimes it stays inside the body for years. The reason
of development of cervical cancer is that keratinocytes
infected with HPV16 do not have the capability to dif-
ferentiate like normal cells and they have close resem-
blance of just the precancerous cervical lesions,
supporting the association between infection with speci-
fic high risk HPV types and the precancerous lesions.
These cells are supposed to be not always malignant or
with a tumorigenic potential but its induction to lead
towards malignancy by the activation of certain onco-
genes it can lead to malignancy [33]. They are now
known to be the most prevalent etiological agents of
cervical and various other anogenital malignancies. The
human papilloma viruses are specifically released by the
desquamating superficial keratinocytes of the infected
stratified epithelia [34]. Its transmission can vary in
aspects such as direct contact and indirect contact.
Direct contact could be a result of contact with infected
tissue and the indirect contact can be with contact of
contaminated objects or surfaces for eg: pool sides. The
transmission of genital HPV is related specifically with
sexual contact. The viral entry leads to a latent infection
which develops within the first three months or it can
remain undetected for years. The lesions are due to
spread because of the infected cells [35].
Cervical cancer the 2
nd most malignancy and its relation
with HPV16
Cervical cancer can also be defined as the cancer origi-
nating at the opening of the womb which progressively
migrates to the whole of cervix [36]. HPV16 is known
to cause cervical cancer and accounts for the majority of
cervical carcinomas in United States and Europe [36,37].
HPV16 is roughly in half of the cervical cancers and
their proteins have been detected extensively in HPV16
and are under observation. HPV 16 is one of the high
risk HPV infections particularly and causes cervical
lesions specifically. The two proteins which play a signif-
icant role in onset of this malignancy are E6 and E7 pro-
teins and their expression has been seen in the cell lines
[37]. IgG and IgA antibodies are associated with HPV16
and are found in CIN in a ratio of about 50-75%. Very
few antibodies are detected in patients who have precan-
cerous cervical lesion.
Back in 1977 statistical data suggested that HPV
viruses are present in cervical epithelium [38]. In differ-
ent cervical smears and biopsies from women who had
CIN, koilocytes were noted which proved that wart
virus antigen and HPV DNA nuclei of cervical epithelial
cells are associated with cervical cancer. These observa-
tions lead to a platform for further research in this area
[39]. The precancerous lesions of CIN2 and CIN3 have
shown positive results for HPV high risk viruses that
develop into invasive cancer. Apart from HPV 16 and
HPV18, other strains such as HPV 31, 33, 35, 39, 45, 51,
52, 56, 58, 59 and 68 leads progressively to invasive cer-
vical cancer whereas mostly low risk HPV types can
lead to condylomata. Analysis from several recent
reports state that HPV 16/18 have a remarkable ability
to immortalize keratinocytes and exhibit a drastic pat-
tern of differentiation.
The most striking and promising evidence that human
papillomaviruses play a pivotal role in oncogenesis is
based on different patterns of HPV DNA in cervical
cells and its integration. The result of integration is dis-
ruption of E1 and E2 gene expression which control the
genes and deregulation of E6 and E7 open reading
frames. The normal function of tumour suppressor
genes p53 and Rb is blocked by the products of E6 and
E7 coding regions [40]. As a result of this blocking
unchecked cellular proliferation takes place allowing the
cell cycle check points to bypass through at G1 and G2
points. By this data it was confirmed that HPV16 pro-
vided the solid evidence for its development in cervical
invasive cancer. HPV DNA was found and present in
about 90% of all cervical cancers [41].
Risk Factors
Keeping in view the association between HPV and Cer-
vical Cancer, early age is thought to be a primary factor
in HPV infection. Its probability increases with the
number of sexual partners at any time of that person’s
life. Epidemiological data shows that the exogenous and
endogenous sex hormones also make a women more
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HPV infection [42]. By analysing different data on Cervi-
cal Cancer, It is indicated by having a check on number
of sexual partners and age at Full Term Pregnancy
(FTP). Cervical Cancer is more common in early preg-
nancies [43] and multiparity displayed changes of female
hormones during pregnancy which showed high risk of
Cervical Cancer in women having high parity. On the
other hand Immune Suppression linked with pregnancy
had more affinity for the risk of new HPV infections as
in pregnancy; body is unable to eliminate the already
existing infections making it more vulnerable to the risk
of neoplastic progression.
Risk factor for Cervical Cancer also increases with the
increase use of Oral Contraceptives (medications taken
by mouth for the purpose of birth control). Women
who use oral contraceptives more than 5 years of dura-
tion had a 3 fold increased in the development of cervi-
cal cancer than those who do not use such type of
medications for birth control. To cap it all, according to
epidemiological studies, the incidence of cervical cancer
and increased risk in multifarious women and with
women using hormonal contraceptives for a long time
were consistent and confirm the hypothesis that female
hormones favours the risk of cervical cancer. It was
more common in women who avoided Pap smears and
also in women who had orthodox religious beliefs such
as church goers [44,45].
Human semen is also considered as the major biologi-
cal basis in sexual behaviour that enhances HPV infec-
tion and cervical cancer. Chronic inflammation of cervix
is due to local cellular and molecular changes that are
reported to be triggered by multiple exposures to semen
[46,47]. Human semen also interacts with cervical
epithelial lining and cells which ultimately affects the
synthesis of cytokines/chemokines which are involved in
the immune response [48]. The most prominent prosta-
glandin PGE2 which is detected in semen play the role
of a common inflammatory mediator. These prostaglan-
dins are detected in 10,000 fold higher concentration at
the site of inflammation [46,47,49]. Up-regulated PGE2
is considered to be the most favourable possible promo-
ter of cervical carcinogenesis. Several studies showed
that smoker’s semen are concentrated with tobacco
related carcinogens and play a role in causing cervical
carcinogenesis [50,51]. Birth control procedures such as
Tubal ligation and Intrauterine devices proved to be one
of the most convincing methods in causing 80% of cer-
vical cancer particularly in developing countries [52,53].
Diagnosis
HPV infection can be clinically diagnosed by the pre-
sence of warts in low risk types. Genital warts which are
sexually transmitted can be present in the form of
cauliflower like smooth popular, small elevated warts.
Progressive cervical disease initiates as a benign non
invasive squamous intraepithelial lesion or CIM. Differ-
ential diagnosis can be done with three procedures of
molecular assays namely: signal amplification, target
amplification, non amplified hybridization assays [54].
Pap smears are the most commonly used lad diagnostic
procedure for women. Cytological changes during HPV
infection which are strongly associated with papaniclav
(pap) smears screening, cell sampling of cervix is done
and checked for signs of malignancy [54]. In pap diag-
nosis atypical squamous cells are of undetermined sig-
nificance (ASCUS) during cervical screening. Although
this diagnosis shows cell abnormality and is not suffi-
cient for definitive diagnosis of a squamous intraepithe-
lial lesion. Colposcpic biopsy is referred to women with
these types of abnormalities [55].
Vaccination
It is now well established fact that Cervical Cancer is
due to HPV infection which is a sexually transmitted
disease. Cervical cancer is among the second most com-
mon cancer in women worldwide. It is a multi-factorial
disease. Various factors are involved in its progression
of cervical cancers such as smoking, sexual behaviour,
age and number of sexual partners [56-64]. Infection is
highly linked to sexual activity with different partners.
HPV associated genital infection are the most prevalent
sexually transmitted infections in various countries
including USA [65,66].
Risk of infection with HPV is directly proportional to
age. Prophylactic HPV Vaccines is found to be effective
in treating HPV infection and it is shown by number of
randomized clinical trials [67-69]. Gardasil, a prophylac-
tic vaccine, shows maximum efficacy if used by girls’
pre-exposure to HPV. Prophylactic HPV Vaccines asso-
ciated with VLPs and are made up of HPV L1 proteins
at present. As VLPs, has no viral DNA therefore these
are not associated with the development of infection
even though their structure is similar to actual virus
morphologically. By intra-muscular (I/M) injection, high
levels of systemic anti HPV L1, Immunoglobulin G anti-
bodies are formed due to VLPs [70].
Prophylactic HPV Vaccines targeting L1 viral protein
which shows increased effectiveness and mostly adopted.
Sexual naïve adolescents should be routinely vaccinated
as recommended by World Health Organization
(WHO). These vaccines can prove to be effective for
future infection instead of previously exposed indivi-
duals. As Papillomavirus is non-lytic virus and can
divide only in epithelial keratinocytes so, prophylactic
vaccines seem to be ineffective in HPV neoplasia. Type
of HPV is correlated with the clinical outcome of infec-
tion. For some infections, host’s immune system
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instantly.
Several vaccination trials have shown that both biva-
lent against HPV 16, 18 and Quadrivalent against HPV
16, 18, 6 and 11 shows remarkable immunological
response which is related to nearly 100% efficacy for a
maximum 5 years in Naïve women [71-75]. Herd immu-
nity is important in showing vaccine effects in women
who are not vaccinated and in those who are reluctant
to have cervical screening and receive vaccination at
very young age. Due to this behaviour, non responders
are about 50% of the screening population in Europe
[76-80] and they are comprised of more than 50% cervi-
cal cancerous cases [81-85]. So, these non responders
should be focused who are unable to get medical ser-
vices in order to increase the public health benefit of
prophylactic vaccination in Europe. Ultimate target is to
have combined benefit among prophylactic vaccination
and services in or cost effective way with maximum
benefit for humanity.
Conclusion
Increase in risk of HPV infection has a tremendous role
in women related sexual problems and the hazardous
effect is in the form of cervical cancer which is the
major cause of death among all the cancers in develop-
ing countries. Avoidance of cervical screening and socio
cultural taboos with special reference in the South East
Asian belt promotes HPV and its strong relation with
cervical cancer. Women are not aware, literate enough
to go for regular pap screening and negative myths or
facts for sexual issues in this region. Women don’tg o
for the treatment of genital warts and the basic purpose
of this review article is to highlight the dire need of
awareness of this deadly cancer.
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